3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
516
Other hematologic neoplasm
223
Plasma cell
84
Myeloid
84
Sarcoma
63
Dermatologic
52
Classical hematology
29
Genitourinary
17
Gynecologic
15
CNS
13
Breast
13
Other neoplasm
9
Thoracic
3
Endocrine
3
Head & Neck
2
Other
1
NET
1
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
169
Carcinoid Tumor
27
Carcinoma, Neuroendocrine
22
Neoplasms
16
Gastro-enteropancreatic neuroendocrine tumor
16
Adenoma, Islet Cell
15
Pancreatic Neoplasms
12
Neoplasm Metastasis
10
Pheochromocytoma
8
Paraganglioma
8
Sarcoma
7
Colorectal Neoplasms
7
Carcinoma
7
Neuroectodermal Tumors, Primitive
6
Neuroblastoma
6
Gastrointestinal Neoplasms
6
Vipoma
5
Somatostatinoma
5
Gastrinoma
5
Cholangiocarcinoma
5
Carcinoma, Islet Cell
5
Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Serotonin Syndrome
4
Digestive System Neoplasms
4
Anus Neoplasms
4
Thyroid Neoplasms
3
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Interventions
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Follicular
×
NET
×
Clear all
NCT02113800
2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2
Completed
40 enrolled